{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:05Z","timestamp":1761709625961,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.aprim.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T08:53:33Z","timestamp":1563180813000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Manejo de la hiperglucemia con f\u00e1rmacos no insul\u00ednicos en pacientes adultos con diabetes tipo 2"],"prefix":"10.1016","volume":"51","author":[{"given":"Fernando","family":"\u00c1lvarez-Guisasola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Orozco-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Cebri\u00e1n-Cuenca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Antonio","family":"Ruiz Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Escarlata","family":"Angullo Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"\u00c1vila Lachica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Ortega Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Caride Miana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Navarro-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Sagredo Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Barrot de la Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc Xavier","family":"Cos Claramunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.aprim.2019.05.014_bib0220","first-page":"S7","article-title":"1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2019.05.014_bib0225","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.pec.2017.06.030","article-title":"Shared decision-making and outcomes in type 2 diabetes: A systematic review and meta-analysis","volume":"100","author":"Saheb Kashaf","year":"2017","journal-title":"Patient Educ Couns."},{"key":"10.1016\/j.aprim.2019.05.014_bib0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4137\/CMED.S20906","article-title":"Health economic evaluation of type 2 diabetes mellitus: A clinical practice focused review","volume":"8","author":"Liebl","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.aprim.2019.05.014_bib0235","first-page":"S61","article-title":"6. Glycemic Targets: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.1016\/j.aprim.2019.05.014_bib0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0212-6567(18)30360-3","article-title":"Recomendaciones preventivas cardiovasculares. Actualizaci\u00f3n PAPPS 2018","volume":"50","author":"Brotons Cuixart","year":"2018","journal-title":"Aten Primaria."},{"key":"10.1016\/j.aprim.2019.05.014_bib0245","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc15-0187","article-title":"Clinical assessment of individualized glycemic goals in patients with type 2 diabetes: Formulation of an algorithm based on a survey among leading worldwide diabetologists","volume":"38","author":"Cahn","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.aprim.2019.05.014_bib0250","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/dom.13243","article-title":"Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2019.05.014_bib0255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.aprim.2015.09.001","article-title":"[Adherence of type 2 diabetes mellitus approach: Current situation and possible solutions]","volume":"48","author":"Orozco-Beltr\u00e1n","year":"2016","journal-title":"Aten Primaria."},{"key":"10.1016\/j.aprim.2019.05.014_bib0260","doi-asserted-by":"crossref","first-page":"e0128581","DOI":"10.1371\/journal.pone.0128581","article-title":"a systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes\u2014Components of interventions","volume":"10","author":"Sapkota","year":"2015","journal-title":"PLoS One."},{"issue":"10120","key":"10.1016\/j.aprim.2019.05.014_bib0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet."},{"year":"2016","series-title":"Gu\u00eda de actualizaci\u00f3n en diabetes mellitus tipo 2","author":"Ezkurra Loiola","key":"10.1016\/j.aprim.2019.05.014_bib0270"},{"key":"10.1016\/j.aprim.2019.05.014_bib0275","unstructured":"Gu\u00eda de diabetes tipo 2 para cl\u00ednicos: Recomendaciones de la redGDPS. 2018."},{"key":"10.1016\/j.aprim.2019.05.014_bib0280","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0290","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [consultado 14 Ene 2019]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm"},{"key":"10.1016\/j.aprim.2019.05.014_bib0295","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin b12 deficiency in the diabetes prevention program outcomes study","volume":"101","author":"Aroda","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.aprim.2019.05.014_bib0300","first-page":"621","article-title":"Optimizing the medical management of diabetic patients undergoing surgery","volume":"70","author":"Tamai","year":"2006","journal-title":"Conn Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0305","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1148\/radiol.09090690","article-title":"Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin","volume":"254","author":"Goergen","year":"2010","journal-title":"Radiology."},{"issue":"Suppl 1","key":"10.1016\/j.aprim.2019.05.014_bib0310","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J Diabetes."},{"key":"10.1016\/j.aprim.2019.05.014_bib0315","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1463-1326.2011.01416.x","article-title":"A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents","volume":"13","author":"Olansky","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2019.05.014_bib0320","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.aprim.2019.05.014_bib0325","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","author":"Arnett","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.aprim.2019.05.014_bib0330","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomized controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.aprim.2019.05.014_bib0335","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0340","unstructured":"AEMPS - Centro de Informaci\u00f3n online de Medicamentos de la AEMPS (CIMA) - Buscador principal [consultado 23 Feb 2019]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=detalleForm"},{"key":"10.1016\/j.aprim.2019.05.014_bib0345","doi-asserted-by":"crossref","DOI":"10.1177\/1179551418786258","article-title":"Combination of empagliflozin and metformin therapy: A consideration of its place in type 2 diabetes therapy","volume":"11","author":"Goldman","year":"2018","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"key":"10.1016\/j.aprim.2019.05.014_bib0350","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aprim.2019.05.014_bib0355","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0360","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial","volume":"2","author":"Rosenstock","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.aprim.2019.05.014_bib0365","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0370","doi-asserted-by":"crossref","first-page":"e82880","DOI":"10.1371\/journal.pone.0082880","article-title":"Safety and efficacy of gliclazide as treatment for type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"9","author":"Landman","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.aprim.2019.05.014_bib0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","article-title":"Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents","volume":"110","author":"Chan","year":"2015","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.aprim.2019.05.014_bib0380","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.aprim.2019.05.014_bib0385","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/dc18-0344","article-title":"Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: A framework for evaluating stratification using routine clinical and individual trial data","volume":"41","author":"Dennis","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2019.05.014_bib0390","unstructured":"Canadian Agency for Drugs and Technologies in Health. Canadian New Drugs for Type 2. Diabetes: Second-Line.Therapy \u2014 Science Report-05-2017 [consultado 15 Feb 2018]. Disponible en: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0012 T2DM Final Recommendations.pdf"},{"key":"10.1016\/j.aprim.2019.05.014_bib0395","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2019.05.014_bib0400","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke."},{"key":"10.1016\/j.aprim.2019.05.014_bib0405","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","article-title":"Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)","volume":"155","author":"Wilcox","year":"2008","journal-title":"Am Heart J."},{"key":"10.1016\/j.aprim.2019.05.014_bib0410","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","article-title":"Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials","volume":"16","author":"De Jong","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.aprim.2019.05.014_bib0415","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"19","author":"Singh","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.aprim.2019.05.014_bib0420","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/DMSO.S130834","article-title":"Glucagon-like peptide-1 receptor agonists: A systematic review of comparative effectiveness research","volume":"10","author":"Levin","year":"2017","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"Supl Extr 4","key":"10.1016\/j.aprim.2019.05.014_bib0425","first-page":"1","article-title":"Inicio de insulinizaci\u00f3n","volume":"08","author":"Artola","year":"2017","journal-title":"Diabetes Pr\u00e1ctica"},{"issue":"Suppl 1","key":"10.1016\/j.aprim.2019.05.014_bib0430","first-page":"1","article-title":"Consenso sobre tratamiento con insulina en la diabetes tipo 2","volume":"65","author":"Girb\u00e9s Borr\u00e1s","year":"2018","journal-title":"Endocrinol Diabetes Nutr."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656719302197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656719302197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:58:10Z","timestamp":1759323490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656719302197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0212656719302197"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2019.05.014","relation":{},"ISSN":["0212-6567"],"issn-type":[{"type":"print","value":"0212-6567"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manejo de la hiperglucemia con f\u00e1rmacos no insul\u00ednicos en pacientes adultos con diabetes tipo 2","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}